Compare Kyndryl Holdings Inc (KD) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kyndryl Holdings Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Kyndryl Holdings Inc trades at $11.83 (market cap $2.67B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Kyndryl Holdings Inc is far larger — about 2.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kyndryl Holdings Inc for 36 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| KD | MRVI | |
|---|---|---|
Market Cap | $2.67B | $972.90M |
Volume | 3,966,787 | 4,325,710 |
Sector | Technology | Health |
52-Week High | $28.92 | $9.00 |
52-Week Low | $10.59 | $2.83 |
Typical Hold Time | 36 Days | 0 Days |
Enterprise Value | $5.49B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kyndryl (KD) trades at $11.79, up slightly by 0.08% with neutral technical indicators. The company shows improving fundamentals with 2025 revenue of $15.06B and a return to profitability with $252M net income after three years of losses. Recent earnings have been mixed with two misses and one beat. Analyst consensus is cautious with 71% hold ratings, though the $14.67 price target suggests 24% upside potential from current levels.
The stock presents a turnaround story with improving cash flow and profitability, but faces execution risks amid competitive pressures. Recent AI-focused initiatives and government contracts provide growth catalysts, though the high P/E ratio of 33.08 requires strong earnings growth to justify valuation. Institutional ownership trends and technical resistance near $12 remain key watchpoints.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
